/
Biological products, (no diagnostic substances) company · P7 · FY ends Dec · Revenue $2.09B · 22.29% margin · $453M FCF
22.29% operating margin is above average. ROIC at 7.51%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue grew 5.7%, steady but not accelerating. Free cash flow declined 10% despite revenue growth, conversion is weakening.
Free cash flow declined 10% versus the prior year, cash generation momentum has weakened.
Profitability & Returns
Revenue (TTM)
$2.09B
▲ +5.7% YoY
Net Income (TTM)
$425M
▲ +408.3% YoY
Op. Margin
22.29%
▲ +17.4pp YoY
ROIC
7.51%
▲ +6.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$453M
▼ -10.5% YoY
Op. Cash Flow (TTM)
$654M
▼ -2.9% YoY
Net Debt
$713M
Cash & Equiv.
$1.10B
5Y CAGR: +2.3%
5Y CAGR: +6.9%
Continue Research